Abstract 2245
Background
Cancer care costs are a major concern for patients and society. We aimed to assess real life costs for the medical management of uMM.
Methods
We performed a retrospective patient chart review collecting data on demographics, disease characteristics and management. A complete registry of patients diagnosed with melanoma at the Antwerp University Hospital between 2007 and 12/2017 was compiled. Eligible for this chart review were all patients with uMM with sufficient data available and who either had an observation period of > 1 year at the time of this review or who deceased before December 31, 2017. Direct costs were calculated by multiplying each item of resource use, obtained from each individual patient chart, with its unit cost (2018, €) using the Belgian public health care payer’s perspective (PHCP) and patient’s perspective. A Kaplan–Meier sample average (KMSA) estimator was used to weight expected costs by the probability of survival and to adjust for censored data.
Results
89 patients fulfilled all eligibility criteria for this chart review. Ten of the patients (11%) are still alive. 9 patients (10%) received best supportive care (BSC) only. 40 patients (45%) received > 1 immunotherapy or targeted agent. Mean overall monthly cost/patient for the entire cohort was € 7,244, of which € 7,153 was covered by the public health care payer. The cost was driven by systemic treatment costs (69% of cost). Median overall survival (OS) was 8.18 months (95 % CI: 6.0-10.3). Mean monthly overall cost was € 9,269 for patients (n = 40) with potential access to anti-PD1, anti-CTLA-4, BRAFi, and MEKi; median OS in this cohort was 13.83 months (95 % CI: 8.6-19.0). Mean monthly overall cost was € 3,258 for patients (n = 33) treated with chemotherapy/BSC only. Median OS in this cohort was 3.91 months (95 % CI: 2.2-5.6). Mean monthly overall cost was € 5,398 for patients (n = 16) who had access to anti-CTLA-4 and/or BRAFi but not to MEKi and anti-PD1. Median OS in these patients was 11.0 months (95 % CI 7.5-14.6).
Conclusions
Management of uMM results in considerable costs for the PHCP, mainly driven by systemic treatment costs. Also in a real-life setting, the introduction of immunotherapy and targeted agents substantially improved survival. However, mean monthly cost has nearly tripled.
Clinical trial identification
Legal entity responsible for the study
Antwerp University Hospital.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4162 - ODM-207 - a novel BET bromodomain inhibitor with antitumor activity in nonclinical models of ER+ breast cancer
Presenter: Anu Moilanen
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3747 - HER2-positive breast cancer resistance to trastuzumab is associated with metabolic switch.
Presenter: Roman Dubianski
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4688 - Combination treatment with the PARP inhibitor niraparib and chemotherapeutics in a preclinical model of KRAS/BRAF mutated colorectal cancer cell lines across the four Consensus Molecular Subtypes.
Presenter: Pietro Paolo Vitiello
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
498 - Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway.
Presenter: Xiao Fu
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3731 - Effect of the polymorphism rs2470893 of the CYP1A1 gene on ovarian and endometrial cancer in Mediterranean women
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1215 - Cisplatin in NIPEC or HIPEC?
Presenter: Ivan Alvovsky
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2738 - Matrix metalloproteinase-mediated regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment
Presenter: MARIKO HIRAI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2190 - Trametinib synergizes with dexamethasone in KRAS-mutant myeloma cell lines through modulation of NDRG1 and induction of apoptosis
Presenter: Priya Sriskandarajah
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4482 - Functional inhibition of TGF-_ in colorectal cancer cells and its interaction with AXL receptor
Presenter: Davide Ciardiello
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
624 - Isoform-specific AKT Inhibition Differentially Affects Cell Functions in Pancreatic Adenocarcinoma
Presenter: Hugo Arasanz
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract